Dr. David Weinstock is a hematologist/oncologist with expertise in hematopoietic stem cell transplantation (HSCT) and has published extensively on clinical complications among transplant recipients. Between 2008-2022, he led a laboratory focused on the intersection between aberrant DNA repair and lymphoid transformation. In 2022, he joined Merck Research Laboratory as Vice President of Discovery Oncology.  In 2025, he moved to Roche, where he is SVP and Global Lead for Oncology at Pharma Research and Early Development.